癌症免疫中的传统型 1 树突状细胞（cDC1）。
Conventional type 1 dendritic cells (cDC1) in cancer immunity.
机构信息
Centre de Recherche des Cordeliers, Equipe Labellisée par la Ligue Contre le Cancer, Université de Paris Cité, Inserm U1138, Institut Universitaire de France, Sorbonne Université, 75006, Paris, France.
Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, 94800, Villejuif, France.
出版信息
Biol Direct. 2023 Nov 1;18(1):71. doi: 10.1186/s13062-023-00430-5.
Cancer immunotherapy, alone or in combination with conventional therapies, has revolutionized the landscape of antineoplastic treatments, with dendritic cells (DC) emerging as key orchestrators of anti-tumor immune responses. Among the distinct DC subsets, conventional type 1 dendritic cells (cDC1) have gained prominence due to their unique ability to cross-present antigens and activate cytotoxic T lymphocytes. This review summarizes the distinctive characteristics of cDC1, their pivotal role in anticancer immunity, and the potential applications of cDC1-based strategies in immunotherapy.
癌症免疫疗法，无论是单独使用还是与传统疗法联合使用，都彻底改变了抗肿瘤治疗的格局，树突状细胞（DC）成为抗肿瘤免疫反应的关键协调者。在不同的 DC 亚群中，传统的 1 型树突状细胞（cDC1）因其独特的抗原交叉呈递和激活细胞毒性 T 淋巴细胞的能力而备受关注。本综述总结了 cDC1 的独特特征、它们在抗癌免疫中的关键作用以及基于 cDC1 的策略在免疫治疗中的潜在应用。
Zotero 插件